Galsulfase: Arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB

Drugs in R and D

Volumn 6, Issue 5, 2005, Pages 312-315

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BM 102; GALSULFASE; RECOMBINANT ENZYME; RECOMBINANT HUMAN ARYLSULFATASE B; RECOMBINANT HUMAN N ACETYLGALACTOSAMINE 4 SULFATASE; UNCLASSIFIED DRUG; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ARTHRALGIA; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FEVER; HEADACHE; HUMAN; MAROTEAUX LAMY SYNDROME; OTALGIA; OTITIS MEDIA; PRIORITY JOURNAL; PRURITUS; REVIEW; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANIMAL; ENZYMOLOGY; MUCOPOLYSACCHARIDOSIS; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; HUMANS; MUCOPOLYSACCHARIDOSES; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 29944440993     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200506050-00008     Document Type: Review

References (8)

1. BioMarin Pharmaceutical Inc. BioMarin Submits U.S. Biologics License Application for Marketing Authorization of Aryplase for MPS VI. Media Release: 29 Nov 2004. Available from URL: http://www.bmrn.com
2. BioMarin Pharmaceutical Inc. FDA Accepts and Grants Six-Month Review for BioMarin's Marketing Application for rhASB for MPS VI. Media Release: 1 Feb 2005. Available from URL: http://www.bmrn.com
3. BioMarin Pharmaceutical Inc. BioMarin Presents Positive Phase II Data on Aryplase for MPS VI. Media Release: 14 Mar 2003. Available from: URL: http://www.biomarinpharm.com
4. BioMarin Pharmaceutical Inc. BioMarin Announces Positive Phase 3 Data on Aryplase(TM) for MPS VI. Media Release: 3 Jun 2004. Available from URL: http://www.bmrn.com
5. BioMarin Pharmaceutical Inc. BioMarin Announces FDA Approval for Naglazyme. Media Release 1 Jun 2005. Available from URL: http://www.bmrn.com
6. BioMarin Pharmaceutical Inc. BioMarin Announces U.S. Launch of Naglazyme for MPS VI. Media Release: 21 Jun 2005. Available from URL: http://www.bmrn.com
7. BioMarin Pharmaceutical Inc. BioMarin Presents Positive Long-Term Results from Ongoing Phase 1 and Phase 2 Clinical Studies of Aryplase for MPS VI. Media Release: 5 Nov 2003. Available from URL: http://www.biomarinpharm.com
8. BioMarin Pharmaceutical Inc. BioMarin's Phase 3 Extension Study of rhASB in MPS VI Demonstrates Additional Improvements in Endurance. Media Release: 9 Mar 2005. Available from URL: http://www.bmrn.com